Makoto Tahara

National Cancer Center Hospital East — Japan

Medicine · Health Sciences

62h-index29.8kcitations600works12.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Head and Neck Cancer Studies(222), Cancer Immunotherapy and Biomarkers(139), Lung Cancer Treatments and Mutations(139), Thyroid Cancer Diagnosis and Treatment(68), Head and Neck Surgical Oncology(48)

Publications595 total

INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Clinical Cancer Research·2025Open Access
Intracranial antitumor efficacy of combination treatment with encorafenib plus binimetinib in BRAF V600E-mutated anaplastic thyroid carcinoma
Auris Nasus Larynx·2025
665O Neoadjuvant and adjuvant pembrolizumab (Pembro) plus standard of care (SOC) for resectable locally advanced head and neck cancer (LA HNSCC) in the Asian subgroup of the phase III KEYNOTE-689 trial
Annals of Oncology·2025
Feasibility of endoscopic response evaluation after induction chemotherapy for determining treatment strategies in esophageal cancer: a post hoc analysis of the CROC trial
Esophagus·2025
Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma
Frontiers in Oncology·2025Open Access
Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in <i>RET</i> -Mutant Medullary Thyroid Cancer
Thyroid·2025· 2 citedOpen Access
PS2-3 Updated efficacy, safety and OS with first-line selpercatinib in advanced RET-mutant medullary thyroid cancer (MTC): LIBRETTO-531
Annals of Oncology·2025
Treatment patterns, outcomes, healthcare resource utilization, and costs associated with locally advanced squamous cell carcinoma of the head and neck in Japan
Frontiers in Oncology·2025Open Access
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study
Journal of Clinical Oncology·2025· 7 citedOpen Access
Giant extrachromosomal element “Inocle” potentially expands the adaptive capacity of the human oral microbiome
Nature Communications·2025Open Access
Microbiota-driven antitumour immunity mediated by dendritic cell migration
Nature·2025· 29 citedOpen Access
Supplementary Data 1 from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2025Open Access
Data from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2025Open Access
LH–RH agonist monotherapy for androgen receptor-positive recurrent and/or metastatic salivary gland cancer: a retrospective study
International Journal of Clinical Oncology·2025· 1 cited
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
New England Journal of Medicine·2025· 157 cited
LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC
Future Oncology·2025· 3 citedOpen Access
Long-Term Clinical Outcomes of Patients with Differentiated Thyroid Cancer Treated with Lenvatinib: Results from Real-World Practice in Japan
Thyroid·2025
Long-term results of the randomized, phase 3 KEYNOTE-412 trial of pembrolizumab (pembro) or placebo (pbo) plus concurrent chemoradiotherapy (CRT) for unresected, locally advanced head and neck squamous cell carcinoma (LA HNSCC).
Journal of Clinical Oncology·2025· 7 cited
Darolutamide plus goserelin for androgen receptor-positive salivary gland cancers: Results of phase 2 study (DISCOVARY).
Journal of Clinical Oncology·2025· 1 cited
Prognostic impact of preoperative imaging-detected extranodal extension in head and neck squamous cell carcinoma treated with postoperative chemoradiotherapy.
Journal of Clinical Oncology·2025
page 1 of 30Next →

Frequent Co-authors

Lisa Licitra(16), Kevin J. Harrington(16), Robert I. Haddad(16), Naomi Kiyota(15), Robert L. Ferris(11), Jérôme Fayette(10), Barbara Burtness(10), Maura L. Gillison(9), J. Guigay(8), Gilberto de Castro(8), Danny Rischin(8), Caroline Even(7), Nabil F. Saba(7), Tamara Rordorf(7), Mark Lynch(7), Richard Greil(7), Amanda Psyrri(7), Thorsten Fuereder(7), Brett Hughes(7), Ricard Mesı́a(7)